A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Donepezil/solifenacin (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Therapeutic Use
- Sponsors Chase Pharmaceuticals
- 21 Jul 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 21 Jul 2017 Status changed from recruiting to active, no longer recruiting.